Bausch (BHC) Starts Litigation Against Amneal for Xifaxan

Bausch Health (BHC) , along with its gastroenterology business, Salix Pharmaceuticals, Inc., announced that it has filed a lawsuit against Amneal Pharmaceuticals (AMRX) and its subsidiaries.The lawsuit was filed on the heels of the Notice of Paragraph IV Certification, stating that Amneal submitted an abbreviated new drug application (ANDA) to the FDA seeking approval to market a generic version of Salix’s lead drug Xifaxan (rifaximin) 550 mg tablets.Xifaxan 550 mg tablets are indicated for the reduction in ...